NDA 020912 · Medicure
Aggrastat
Tirofiban Hydrochloride · Injection
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: May 16, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
May 14, 1998
Approved uses
2
Original approval plus efficacy supplements
Registered trials
69
25 Phase 3, 10 recruiting
FAERS reports
2,780
2,466 serious, 442 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 1, 2025.
AGGRASTAT® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). AGGRASTAT is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Mechanism: AGGRASTAT is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. When administered intravenously, AGGRASTAT inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the PRISM-PLUS regimen of 0.4 mcg/kg/min over 30 minutes followed by a 0.1 mcg/kg/min maintenance infusion, >90% inhibition of platelet aggregation is attained by the end of the 30-minute infusion. When given according to the recommended regimen of 25 mcg/kg followed by a 0.15 mcg/kg/min...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 10, 2013 Supplement 19 · Efficacy LabelLetter
- May 14, 1998 Original approval · Type 1 - New Molecular Entity · priority review LetterLabel
2 products under this application
- AGGRASTAT · TIROFIBAN HYDROCHLORIDE EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML) · SOLUTION, INJECTION · Prescription
- AGGRASTAT · TIROFIBAN HYDROCHLORIDE EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML) · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Tirofiban" as an intervention, any sponsor and status, largest first.
- Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4)Pivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT06319846 · 4,674 participants (planned) · Start Jul 11, 2024 · Primary completion Oct 2025
Drug: Tirofiban; Placebo · For: Ischemic Stroke, Acute; TIA; Symptomatic Intracranial Artery Stenosis
Sites: Harbin, China; Dezhou, China; Liaocheng, China · 5 sites in all
- Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00251576 · 4,497 participants · Start Nov 1, 1999 · Primary completion Mar 23, 2004
Drug: A-Phase: tirofiban; Z-Phase simvastatin; Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years and 3 more · For: Acute Coronary Syndrome
- European Ambulance Acute Coronary Syndrome (ACS) Angiography TrialPivotal-lookingCompleted
The Medicines CompanyIndustry
NCT01087723 · 2,198 participants · Start Mar 2010 · Primary completion Aug 2013
Drug: Bivalirudin; Heparin · For: Acute Coronary Syndrome
Sites: Vienna, Austria; České Budějovice, Czechia; Aarhus, Denmark · 145 sites in all
- BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.Pivotal-lookingCompleted
Shenyang Northern HospitalAcademic, hospital or other
NCT01696110 · 2,194 participants · Start Aug 2012 · Primary completion Jul 2013
Drug: Bivalirudin; heparin and 1 more · For: Acute Myocardial Infarction; Percutaneous Coronary Intervention
Sites: Hefei, China; Beijing, China; Chongqing, China · 81 sites in all
S. Anna HospitalAcademic, hospital or other
NCT00566891 · 2,000 participants · Start Dec 2007 · Primary completion Jul 2008
Drug: tirofiban; Clopidogrel · For: Coronary Artery Disease
Sites: Catanzaro, Italy
- Tirofiban After Successful MT Recanalization in AISPivotal-lookingCompleted
Xiang LuoAcademic, hospital or other
NCT06265051 · 1,380 participants · Start Apr 9, 2024 · Primary completion Dec 29, 2025
Drug: Tirofiban; Saline placebo · For: Acute Ischemic Stroke; Vessel Occlusion
Sites: Wuhan, China
- A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic StrokePivotal-lookingNot yet recruiting
Xinqiao Hospital of ChongqingAcademic, hospital or other
NCT07842185 · 1,192 participants (planned) · Start Dec 19, 2026 · Primary completion Dec 30, 2030
Drug: Tirofiban Injection; Tirofiban Injection · For: Acute Ischemic Stroke
Sites: Fuyang, China; Longyan, China; Xiangtan, China · 10 sites in all
- Tirofiban Combined With Aspirin in Moderate Ischemic StrokePivotal-lookingNot yet recruiting
Xinqiao Hospital of ChongqingAcademic, hospital or other
NCT07760922 · 1,168 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 31, 2028
Drug: Tirofiban; Tirofiban-matching placebo · For: Ischemic Stroke, Acute
Sites: Haikou, China; Jingdezhen, China; Jiujiang, China · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- haemorrhage376
- thrombocytopenia295
- myocardial infarction206
- angina pectoris187
- haemorrhage intracranial179
- death146
- cardiac failure acute118
- cerebral haemorrhage110
- acute respiratory failure99
- cardiac failure88
- vascular stent thrombosis80
- infarction53
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 45 |
| 2005 | 169 |
| 2006 | 134 |
| 2007 | 59 |
| 2008 | 19 |
| 2009 | 7 |
| 2010 | 10 |
| 2011 | 11 |
| 2012 | 31 |
| 2013 | 15 |
| 2014 | 12 |
| 2015 | 14 |
| 2016 | 44 |
| 2017 | 74 |
| 2018 | 98 |
| 2019 | 1,159 |
| 2020 | 236 |
| 2021 | 137 |
| 2022 | 305 |
| 2023 | 23 |
| 2024 | 66 |
| 2025 | 29 |
| 2026 | 83 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.
Tao C, Liu T, Cui T, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial.
Zhao W, Li S, Li C, et al. · JAMA Neurol 2024 · Randomized Controlled Trial, Multicenter Study
- Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion.
Zi W, Song J, Kong W, et al. · N Engl J Med 2023 · Clinical Trial, Multicenter Study
- Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week.
Sullivan AE, Nanna MG, Wang TY, et al. · J Am Coll Cardiol 2021 · Systematic Review
- Effect of Intravenous Tirofiban vs Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The RESCUE BT Randomized Clinical Trial.
Qiu Z, Li F, Sang H, et al. · JAMA 2022 · Comparative Study, Multicenter Study
- Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: The INSTANT Randomized Clinical Trial.
Liu X, Zhang F, Zhang C, et al. · JAMA 2026 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Medicure
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.